MetaCap

Perspective Therapeutics (CATX) vs Equillium (EQ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Equillium (EQ) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 10.4% versus a loss of 63.9%. Over five years, EQ leads with a -80.4% price change compared with -84.6% for CATX. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%EQ+10.42%
+248%+85%-79%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%EQ-79.81%
+288%+88%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus EQ key metrics
MetricCATXEQ
Share price$0.7538$1.06
Market cap$91.03M$87.26M
1-day change-3.85%-5.36%
YTD return-72.59%-31.61%
1-year return-63.93%+10.42%
5-year return-84.62%-80.41%
EPS (TTM)$-1.25$-0.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-103.12M$-22.40M
52-week high$6.16$3.54
52-week low$0.73$0.81
Distance from 52-week high-87.76%-70.06%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+707.55%
Average volume2.70M544.39K
Shares outstanding120.76M82.32M
Employees16314
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EQ has outperformed CATX by 74.3 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

CATX vs EQ FAQ

Which is bigger, Perspective Therapeutics or Equillium?

Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.26M for Equillium (EQ).

Which stock has performed better over the past year, CATX or EQ?

EQ returned +10.42% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and Equillium in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons